Antiemicranici specifici in Europa e nel mondo

This paper deals with symptomatic treatment, which is the first therapeutic approach in patients with migraine. It focuses, in particular, on specific anti-migraine treatments and on the few, but valuable, data on their daily use in different countries, both European and elsewhere in the world. This would seem to be a very important topic, given that the vast majority of migraine patients take symptomatic drugs, prescribed or not prescribed by their doctor, in order to reduce the symptoms of the attack, namely pain but also nausea, photophobia and phonophobia, with the immediate objective of freeing themselves from these (more or less often disabling) symptoms and resuming their activities as quickly as possible.